Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis

  • M. Chowers
  • B.-S. Gottesman
  • L. Leibovici
  • J. M. Schapiro
  • M. Paul
Article

Abstract

Treatment guidelines recommend dual nucleoside reverse transcriptase inhibitors (NRTI ) as a part of combination antiretroviral therapy. The objective of this study was to assess the relative efficacy and toxicity of the dual NRTI part of the regimen in antiretroviral-naïve HIV-1-infected adults. A systematic review and meta-analysis of randomized controlled trials assessing highly active antiretroviral therapy (HAART) for treatment-naïve HIV-infected adults with a 48-week follow-up were done. We searched the PubMed, CENTRAL, and EMBASE electronic databases up to April 2009. Proceedings from conferences were reviewed. Data were extracted independently by two reviewers. Primary outcome was viral suppression at 48 weeks. The odds ratio (OR) is reported with its corresponding 95% confidence interval (CI). Twenty-two randomized controlled trials, including 8,184 HIV-treatment-naïve patients, were included. The combination didanosine + lamivudine/emtricitabine (four trials, 1,148 patients) was more effective (OR 0.53, 95% CI 0.41–0.68) for viral load (VL) >50 copies/ml and less toxic (OR 0.52, 95% CI 0.36–0.76) for discontinuation due to adverse events (AE) than its comparators. The combination tenofovir + lamivudine/emtricitabine was more effective and less toxic (OR 0.75, 95% CI 0.58–0.96) only in the 144-week follow-up data (two trials, 1,119 patients). Abacavir + lamivudine had similar efficacy to its comparators (OR 0.81, 95% CI 0.8–1.1), but more AIDS-defining events (OR 3.22, 95% CI 1.24, 8.40). The once-daily combination didanosine + lamivudine/emtricitabine was found to be effective and tolerable. This combination, soon to be generic, should be compared to the current standard of care in a large randomized trial. An effective, safe, and inexpensive alternative to current options is needed.

References

  1. 1.
    Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133(1):21–30PubMedGoogle Scholar
  2. 2.
    Panel on Antiretroviral Guidelines for Adults and Adolescents (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available online at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Cited May 2009
  3. 3.
    Clumeck N, Pozniak A, Raffi F (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 9(2):65–71CrossRefPubMedGoogle Scholar
  4. 4.
    Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F (2006) An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 20(16):2051–2064CrossRefPubMedGoogle Scholar
  5. 5.
    Higgins JPT, Green S (eds) Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b. In: The Cochrane Library, Issue 3, 2005. John Wiley & Sons, Ltd., Chichester, UKGoogle Scholar
  6. 6.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560CrossRefPubMedGoogle Scholar
  7. 7.
    Berenguer J, González J, Ribera E, Domingo P, Mirales P, Ribas MA, Asensi V, Gimeno JL, Terrón JA, Pérez Molina JA (2007) Didanosine, lamivudine and efavirenz vs zidovudine, lamivudine and efavirenz, for initial treatment of HIV infection over 48 weeks: a randomized non-inferiority clinical trial, GESIDA 3903. ICAAC, Chicago, ILGoogle Scholar
  8. 8.
    Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Arici C, Ravasio L, Suter F (2003) Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 8(4):339–346PubMedGoogle Scholar
  9. 9.
    Saag MS, Cahn P, Raffi F, Wolff M, Pearce D, Molina JM, Powderly W, Shaw AL, Mondou E, Hinkle J, Borroto-Esoda K, Quinn JB, Barry DW, Rousseau F (2004) Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 292(2):180–189CrossRefPubMedGoogle Scholar
  10. 10.
    Maggiolo F, Ripamonti D, Migliorino G, Martinelli C, Sighinolfi L, Quinzan G, Gregis G, Abeli C, Airold i M, Suter F (2006) Comparison of three once-a-day regimens as first-line HAART. In Proceedings of the AIDS 2006—XVI International AIDS Conference, Toronto, Canada, August 2006Google Scholar
  11. 11.
    Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ, Cheng AK (2008) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47(1):74–78CrossRefPubMedGoogle Scholar
  12. 12.
    Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354(3):251–260CrossRefPubMedGoogle Scholar
  13. 13.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2):191–201CrossRefPubMedGoogle Scholar
  14. 14.
    Sax P, Tierney C, Collier A, Fischl M, Godfrey C, Jahed N, Droll K, Peeples L, Myers L, Thal G, Rooney J, Ha B, Woodward W, Daar E (2008) ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA 100,000 c/mL. In: Proceedings of the AIDS 2008—XVII International AIDS Conference, Mexico City, August 2008Google Scholar
  15. 15.
    Smith K, Fine D, Patel P, Bellos N, Sloan L, Lackey P, Sutherland-Phillips D, Vavro C, Liao Q, Shaefer M (2008) Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study. In: Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 2008Google Scholar
  16. 16.
    DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR (2004) Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39(7):1038–1046CrossRefPubMedGoogle Scholar
  17. 17.
    Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L (2007) Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 44(2):139–147CrossRefPubMedGoogle Scholar
  18. 18.
    MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M (2004) Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clin Trials 5(6):361–370CrossRefPubMedGoogle Scholar
  19. 19.
    Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA (2000) A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 14(9):1171–1180CrossRefPubMedGoogle Scholar
  20. 20.
    Domula MR, Wasmuth JC, Jütte A, Fätkenheuer G, Oette M, Theisen A, Höhn C, Knechten H, Pfeil B, Fenske S, Rieke A, Rockstroh JK (2002) A comparison of AZT/3TC vs 3TC/d4T and ddI/d4T in combination with efavirenz as first line therapy: efficacy and safety results after 48 weeks. In: Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, February 2002Google Scholar
  21. 21.
    Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA (2006) A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 7(2):85–98CrossRefPubMedGoogle Scholar
  22. 22.
    Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M (2000) A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 14(11):1591–1600CrossRefPubMedGoogle Scholar
  23. 23.
    French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D (2002) Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials 3(3):177–185CrossRefPubMedGoogle Scholar
  24. 24.
    Antela A, Iribarren JA, Mahillo B, Santos I, Ribera E, Gutierrez C, Esteban H, Labarga P, González J, Andia A, Marti-Belda P (2004) Final analysis of a prospective, randomized, open-label, multicenter trial in naive, HIV-1-infected patients, comparing ZDV/3TC vs d4T/ddI, plus Efavirenz, Nevirapine or Indinavir/Ritonavir (AMADEUS 01 study). In: Proceedings of the XV International AIDS Conference, Bangkok, Thailand, July 2004Google Scholar
  25. 25.
    Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS (2000) Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 14(6):671–681CrossRefPubMedGoogle Scholar
  26. 26.
    Gathe J Jr, Badaro R, Grimwood A, Abrams L, Klesczewski K, Cross A, McLaren C (2002) Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir. J Acquir Immune Defic Syndr 31(4):399–403PubMedGoogle Scholar
  27. 27.
    Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D’Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349(24):2304–2315CrossRefPubMedGoogle Scholar
  28. 28.
    Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E (2008) Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 47(8):1083–1092CrossRefPubMedGoogle Scholar
  29. 29.
    Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR (2006) Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296(7):769–781CrossRefPubMedGoogle Scholar
  30. 30.
    Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G, Fisher M, Gazzard B (2005) A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 55(2):246–251CrossRefPubMedGoogle Scholar
  31. 31.
    Carr A (2002) Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 360(9326):81–85CrossRefPubMedGoogle Scholar
  32. 32.
    Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M (2000) A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 14(11):1601–1610CrossRefPubMedGoogle Scholar
  33. 33.
    Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371(9622):1417–1426CrossRefPubMedGoogle Scholar
  34. 34.
    Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A (2001) Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 33(11):1931–1937CrossRefPubMedGoogle Scholar
  35. 35.
    Dragovic G, Milic N, Jevtovic DJ (2005) Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage. Int J STD AIDS 16(6):427–429CrossRefPubMedGoogle Scholar
  36. 36.
    Guo JJ, Jang R, Louder A, Cluxton RJ (2005) Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus. Pharmacotherapy 25(8):1044–1054CrossRefPubMedGoogle Scholar
  37. 37.
    Smith CJ, Mocroft A, Lundgren JD (2008) Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. AIDS 22(8):997–998CrossRefPubMedGoogle Scholar
  38. 38.
    Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD (2005) Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40(1):148–157CrossRefPubMedGoogle Scholar
  39. 39.
    Carr A, Amin J (2009) Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 23(3):343–353; discussion 355–346CrossRefPubMedGoogle Scholar
  40. 40.
    Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22(14):F17–F24CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • M. Chowers
    • 1
    • 2
  • B.-S. Gottesman
    • 1
    • 2
  • L. Leibovici
    • 1
    • 3
  • J. M. Schapiro
    • 4
  • M. Paul
    • 1
    • 3
  1. 1.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Infectious Disease UnitMeir Medical CenterKfar SabaIsrael
  3. 3.Rabin Medical Center, Beilinson CampusPetah-TiqvaIsrael
  4. 4.National Hemophilia CenterSheba Medical CenterTel HashomerIsrael

Personalised recommendations